Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.
Abstract: A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.
Type:
Grant
Filed:
June 2, 2017
Date of Patent:
May 24, 2022
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Inventors:
Steven Greenberg, Stefano Vincenzo Gulla, Kenneth Evan Thompson
Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.
Abstract: The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.
Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.
Type:
Grant
Filed:
March 30, 2021
Date of Patent:
March 15, 2022
Assignee:
Chugai Seiyaku Kabushiki Kaisha
Inventors:
Sotaro Naoi, Shu Feng, Tomoyuki Igawa, Shu Wen Samantha Ho
Abstract: A polypeptide having a sequence at least 60% identical to SEQ ID NO: 1 (WFEWPYWEMNVPDVWN) is provided. The polypeptide includes no more than 100 total amino acid residues.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
February 22, 2022
Assignee:
3M Innovative Properties Company
Inventors:
Minghua Dai, Amy K. McNulty, Federica Sgolastra, Jie Liu, Jana Ninkovic, Robert T. Fitzsimons, Jr.
Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for modulation of dietary and microbial exposure. The present disclosure provides for compositions and methods for treating, preventing, or reducing the likelihood of development of an allergic disorder, necrotizing enterocolitis, sepsis, or an inflammatory disease, disorder, or condition in a subject including administering an effective amount of a composition comprising an EGFR ligand.
Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.
Type:
Grant
Filed:
July 9, 2018
Date of Patent:
February 1, 2022
Assignee:
VERSITECH LIMITED
Inventors:
Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
Abstract: The present invention provides an antagonist of a Bcl-2 prosurvival protein containing a BH3-like domain. The antagonist of the invention comprises ARTS and any fragment or peptide that comprises a BH3-like domain. The invention further provides compositions, combined compositions and kits as well as methods for treating Bcl-2 over-expressing disorders.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
January 25, 2022
Assignee:
CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
Type:
Grant
Filed:
October 18, 2018
Date of Patent:
January 11, 2022
Assignee:
Cephalon, Inc.
Inventors:
Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget A. Cooksey, Vanya Pande, Adam W. Clarke
Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Grant
Filed:
March 6, 2018
Date of Patent:
January 4, 2022
Assignee:
ROCHE GLYCART AG
Inventors:
Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
Abstract: High affinity SIRP-? reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRP? reagent, which blocks the physiological binding interaction between SIRP? and its ligand CD47.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
December 28, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron M. Levin, Irving L. Weissman
Abstract: Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.
Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.
Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
October 26, 2021
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
Abstract: This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and/or CD8+ T cell killing) are provided.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
October 5, 2021
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
Type:
Grant
Filed:
November 23, 2020
Date of Patent:
October 5, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman